Evaluating cardiac risk: exposure response analysis in early clinical drug development
{{output}}
The assessment of a drug's cardiac liability has undergone considerable metamorphosis by regulators since International Council for Harmonization of Technical Requirement for Pharmaceuticals for Human Use E14 guideline was introduced in 2005. Drug developers n... ...
